Vertex Pharmaceuticals reported third-quarter 2026 total revenue of $3.44 billion, representing a 12% increase compared to the same period in 2025, driven by cystic fibrosis therapies and newer product growth. The company raised its full-year 2026 revenue guidance to $13.15 billion to $13.25 billion following strong performance and the closing of the Crinetics Pharmaceuticals acquisition. GAAP net income declined year-over-year to $654 million due to acquisition-related expenses.
Total revenue for the third quarter of 2026 reached $3.44 billion, up 12% year-over-year.
Full-year 2026 revenue guidance was raised to a range of $13.15 billion to $13.25 billion.
GAAP net income was $654 million for the third quarter of 2026, compared to $1.1 billion in the third quarter of 2025.
The acquisition of Crinetics Pharmaceuticals closed on September 1, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Vertex Pharmaceuticals's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$12.00B
+8.9%
$15.32
—
32.9%
FY2024
$11.02B
+11.7%
$-2.08
-115.0%
-4.9%
FY2023
$9.87B
+10.5%
$13.89
+8.3%
36.7%
FY2022
$8.93B
+17.9%
$12.82
+42.3%
37.2%
FY2021
$7.57B
+22.1%
$9.01
-12.4%
30.9%
Frequently asked questions
When is Vertex Pharmaceuticals's next earnings date?
Vertex Pharmaceuticals has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Vertex Pharmaceuticals earn last quarter?
For the quarter ended Sep 2026, Vertex Pharmaceuticals reported diluted EPS of $2.56 (-39.0% year over year) on revenue of $3.44B (+11.8%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.